Tyra Biosciences price target raised to $53 from $37 at Wedbush

Wedbush analyst Robert Driscoll raised the firm’s price target on Tyra Biosciences (TYRA) to $53 from $37 and keeps an Outperform rating on the shares. The firm notes BridgeBio (BBIO) announced positive topline Phase 3 data for infigratinib in achondroplasia, providing validation for FGFR3 inhibition as an on-target mechanism for height velocity increases in skeletal dysplasia patients. Wedbush views this data as particularly encouraging for dabogratinib, as a more selective FGFR3 inhibitor will likely demonstrate significant further increases in absolute AHV, with potential for significant and clinically important changes in proportionality.

Valentine's Day Sale - 70% Off

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on TYRA:

Disclaimer & DisclosureReport an Issue

Tyra Biosciences participates in a coferejce call with William Blair Tyra Biosciences initiated with an Outperform at William Blair Tyra Biosciences Advances BEACH301 Dose Escalation Tyra Biosciences price target raised to $50 from $36 at Oppenheimer Tyra Biosciences initiated with an Overweight at Barclays

View Comments